| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(16 days from now) | |
Fensolvi Kit is owned by Tolmar.
Fensolvi Kit contains Leuprolide Acetate.
Fensolvi Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Fensolvi Kit was authorised for market use on 01 May, 2020.
Fensolvi Kit is available in powder;subcutaneous dosage forms.
Fensolvi Kit can be used as method of treating pediatric patients 2 years of age and older with central precocious puberty.
The generics of Fensolvi Kit are possible to be released after 15 October, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | May 1, 2023 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
FENSOLVI KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic